HLB Pharmaceutical Co., Ltd (047920.KQ)
KRW 23050.0
(-1.5%)
KRW 23050.0
(-1.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -19.54 Billion KRW | -192.81% |
| 2022 | -6.94 Billion KRW | -3029.93% |
| 2021 | 236.89 Million KRW | -63.34% |
| 2020 | 646.1 Million KRW | -35.91% |
| 2019 | 1 Billion KRW | 116.5% |
| 2018 | -6.11 Billion KRW | -47.15% |
| 2017 | -4.15 Billion KRW | -786.0% |
| 2016 | 605.4 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.21 Billion KRW | 128.38% |
| 2024 Q2 | 554.32 Million KRW | -47.81% |
| 2023 Q3 | -7.6 Billion KRW | 13.46% |
| 2023 FY | -20.32 Billion KRW | -192.81% |
| 2023 Q4 | -4.28 Billion KRW | 43.7% |
| 2023 Q2 | -8.79 Billion KRW | -1445.84% |
| 2023 Q1 | 653.28 Million KRW | 128.0% |
| 2022 FY | -6.94 Billion KRW | -3029.93% |
| 2022 Q1 | -2.08 Billion KRW | -133.65% |
| 2022 Q4 | -2.33 Billion KRW | -29.6% |
| 2022 Q3 | -1.8 Billion KRW | -525.04% |
| 2022 Q2 | -288.02 Million KRW | 86.18% |
| 2021 Q3 | 1.12 Billion KRW | 0.0% |
| 2021 FY | 236.89 Million KRW | -63.34% |
| 2021 Q4 | -892.08 Million KRW | -179.47% |
| 2020 FY | 646.1 Million KRW | -35.91% |
| 2019 FY | 1 Billion KRW | 116.5% |
| 2018 FY | -6.11 Billion KRW | -47.15% |
| 2017 FY | -4.15 Billion KRW | -786.0% |
| 2016 FY | 605.4 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | 441.336% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | 154.177% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 115.898% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | 129.223% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | -36.124% |
| Humedix Co., Ltd. | 37.31 Billion KRW | 152.378% |
| Boditech Med Inc. | 33.44 Billion KRW | 158.434% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | 353.824% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | -132.426% |
| Huons Co., Ltd. | 59.79 Billion KRW | 132.682% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | 280.634% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | -19.352% |